ClinicalTrials.gg
CompletedNCT06202079Updated Jan 23, 2025

A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus

A Phase 2 interventional study of GZR4 Injection and Insulin Degludec in Diabetes Mellitus, Type 2, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 8 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Gan & Lee Pharmaceuticals.

Enrollment
7th of 17
179 · median 92
Started
2023
with 2 others
Phase 2
6 of 17
2 open now
Registered
4th of 17
by date

Among the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, this one is the 7th largest by enrollment, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetes Mellitus, Type 2 by Gan & Lee Pharmaceuticals, or all of them as a file.
02

Study summary

This study compares the efficacy, safety, and tolerability of once-weekly GZR4 Injection versus once-daily insulin degludec in patients with type 2 diabetes mellitus in inadquete control on oral antidiabetic drug (OAD) therapy or OAD Therapy in combination with basal insulin.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-75 years (both inclusive) at the time of signing form (ICF)
  2. between 18.5 and 35.0 kg/m2 (both inclusive)
  3. Diagnosed with type 2 diabetes mellitus above or equal to 6 months
  4. 7.5% ≤ ≤ 10.0% at screening.

Exclusion criteria

Exclusion Criteria:

  1. Female who is pregnant, breast-feeding.
  2. Presence or history of malignant neoplasm prior to screening.
  3. Diabetic ketoacidosis, diabetic lactic acidosis, or diabetic nonketotic hyperosmolar syndrome within 6 months prior to screening.
  4. Known or suspected to medical product(s) or related products.
  5. Severe hypoglycemia (Level 3 hypoglycemia) within 6 months prior to screening
  6. History of acute heart failure within 6 months prior to screening or hospitalization for coronary heart disease, myocardial infarction, unstable angina, stroke within 6 months prior to screening.
  7. Participation in a clinical study of another study drug within 3 month prior to randomization.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    GZR4 Injection

    GZR4 Injection + Oral Antidiabetic Drug

    Drug: GZR4 Injection

  • Active comparator
    Insulin Degludec

    Insulin Degludec + Oral Antidiabetic Drug

    Drug: Insulin Degludec

Interventions

  • DrugGZR4 Injection

    GZR4 injection s.c., once-weekly, treat-to-target dose

  • Insulin Degludec s.c., once-daily, treat-to-target dose

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change from baseline in HbA1c after 16 weeks of treatment

    Time frame: From baseline (week 0) to week 16

Secondary outcomes

  1. Change in fasting plasma glucose(FPG)

    Change from baseline in fasting plasma glucose (FPG) after 16 weeks of treatment

    Time frame: From baseline (week 0) to week 16

  2. Weekly doses of GZR4 Injection/Insulin Degludec

    Weekly doses of once-weekly GZR4 Injection and once-daily Insulin Degludec Injection from week 15 to week 16 are presented.

    Time frame: Week 15-16

  3. Incidence and Rate of Treatment-emergent adverse events (TEAEs)

    A TEAE is defined as an event that had onset date (or increase in severity) during the on-treatment observation period.

    Time frame: From baseline (week 0) to week 20

  4. Incidence and Rate of hypoglycemia episodes

    Hypoglycaemia alert episodes (level 1) are defined as episodes that are sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and less than (\<) 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by blood glucose (BG) meter. Clinically significant hypoglycaemic episodes (level 2) are defined as episodes that are sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) are defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Severe hypoglycaemic episodes (level 3) are defined as episodes that are associated with severe cognitive impairment requiring external assistance for recovery.

    Time frame: From baseline (week 0) to week 20

  5. Change in ADA of GZR4

    Blood samples will be analysed for anti-GZR4 antibodies

    Time frame: From baseline (week 0) to week 16

  6. Change in Nab of GZR4

    Blood samples will be analysed for Nab

    Time frame: From baseline (week 0) to week 16

07

Study locations

8 sites
  • Study Site 07
    Wuhan, Hubei, China
  • Study Site 06
    Changzhou, Jiangsu, China
  • Study Site 08
    Jinan, Shandong, China
  • Study Site 04
    Zibo, Shandong, China
  • Study Site 03
    Xi'an, Shanxi, China
  • Study Site 02
    Beijing, China
  • Study Site 05
    Beijing, China
  • Study Site 01
    Tianjin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jul 2024, 11 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2024
First posted
Jan 11, 2024
StartActual
Aug 11, 2023
Primary completionActual
Jul 13, 2024
CompletionActual
Aug 8, 2024
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06202079
Responsible party
Sponsor
First posted
Jan 11, 2024
Start date
Aug 11, 2023
Primary completion
Jul 13, 2024
Completion
Aug 8, 2024
Last update
Jan 23, 2025

Study contacts

Chunyue Hao
study director · Gan & Lee Pharmaceuticals.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion